


FGFR-IN-10

Cat. No.:	HY-148597
CAS No.:	2847092-41-3
Molecular Formula:	C ₂₈ H ₃₀ FN ₉ O ₂
Molecular Weight:	543.6
Target:	FGFR; Cytochrome P450
Pathway:	Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC ₅₀ s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC ₅₀ s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively ^[1] .							
IC₅₀ & Target	CYP2C9 3.33 μM (IC ₅₀)	CYP2C19 18.75 μM (IC ₅₀)	CYP2D6 4.34 μM (IC ₅₀)	CYP3A4 0.69 μM (IC ₅₀)				
	FGFR2 104.1 nM (IC ₅₀)	V564F-FGFR2 43.6 nM (IC ₅₀)						
In Vitro	FGFR-IN-10 (compound 115) (5 μM; 0-240 min) was stable in the blood of SD rats and human, and its whole blood half-life (t _{1/2}) was >600 min ^[1] . FGFR-IN-10 (0-10 μM; 72 h) inhibits the growth of SNU-16 and JMSU-1 cells with GI ₅₀ s of 6 nM and 24 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.							
In Vivo	FGFR-IN-10 (10 mg/kg; p.o.; single dose) shows potent oral activity in SD rats, with bioavailability of 60.7% ^[1] . Pharmacokinetic Analysis in SD Rats ^[1]							
	Route	Dose (mg/kg)	C _{max} (ng/mL)	AUC _{last/D} (h·mg/mL)	T _{1/2} (h)	Cl _{obs} (mL/min/kg)	V _{ss_obs} (L/kg)	F (%)
	i.v.	5	/	664	1.02	26.0	1.2	/
	p.o.	10	2388	402	/	/	/	60.7
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.							

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA